Search alternatives:
decrease » decreased (Expand Search), increase (Expand Search)
cost » most (Expand Search)
Showing 1 - 20 results of 137 for search '(((( 5 ng decrease ) OR ( _ cost decrease ))) OR ( _ breast decrease ))', query time: 0.14s Refine Results
  1. 1

    A slow but steady nanoLuc: R162A mutation results in a decreased, but stable, nanoLuc activity by Wesam S. Ahmed (10170053)

    Published 2024
    “…Here, we combined molecular dynamics (MD) simulation and mutational analysis to show that the R162A mutation results in a decreased but stable <u>bioluminescence </u>activity of NLuc in living cells and in vitro. …”
  2. 2

    Cost-benefit analysis of antimicrobial stewardship program in a cancer setting in Qatar by Dina Abushanab (10696501)

    Published 2024
    “…Cost avoidance was the expenses saved due to decreased hospital stays and fewer adverse drug events (ADEs). …”
  3. 3

    Cost-Benefit Analysis of Antimicrobial Stewardship Program in the Adult General Medicine Setting in Qatar by Dina Abushanab (10696501)

    Published 2024
    “…</p><h3> Results</h3><p dir="ltr">The operational costs of the program decreased with maturity by cost savings of QAR125 per 100-patient beds per year. …”
  4. 4

    The cost associated with the development of the antimicrobial stewardship program in the adult general medicine setting in Qatar by Dina Abushanab (10696501)

    Published 2024
    “…</p><h3>Results</h3><p dir="ltr">A total of 500 patients were included in the study. The operational costs decreased with the developed ASP. Whereas antimicrobial consumption and resource utilisation, and their associated costs, appear to have declined with the developed ASP, with a cost saving of QAR458 (US$125) per 100-patient beds, the avoided cost was negative, by QAR4,807 (US$1,317) per 100-patient beds, adding to a total QAR4,224 (US$1,160) increase in the 100-patient beds cost after ASP development.…”
  5. 5

    Immunomodulatory effects of tumor Lactate Dehydrogenase C (LDHC) in breast cancer by Adviti Naik (673163)

    Published 2025
    “…Silencing LDHC in breast cancer cell lines (MDA-MB-468, BT-549, HCC-1954) enhanced early T cell activation and cytolytic activity. …”
  6. 6

    miRNA-dependent regulation of STIM1 expression in breast cancer by Rashmi P. Kulkarni (18618634)

    Published 2019
    “…<p dir="ltr">Store-operated Ca<sup>2+</sup> entry (SOCE) has been shown to be important for breast cancer metastasis in xenograft mouse models. …”
  7. 7

    Modulation of SLFN11 induces changes in DNA Damage response in breast cancer by Christophe Michel Raynaud (17449906)

    Published 2023
    “…Our results show that induction of SLFN11 expression can enhance DDA and DDR sensitivity in breast cancer cells and dCas9 systems may represent a novel approach to increase SLFN11 and achieve higher sensitivity to chemotherapeutic agents, improving outcome or decreasing required drug concentrations. …”
  8. 8

    Characterizing the Protein Coding RNAs (mRNA) and Long Non-Coding RNAs (LncRNAs) in Chemo Resistant Triple Negative Breast Cancer by Ahmed Mahmoud Mahmoud Mohamed Kardousha (19926096)

    Published 2023
    “…Breast Cancer (BC) is the most diagnosed cancer type in both genders according to the world health organization. …”
  9. 9

    Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis by Wouter Hendrickx (44559)

    Published 2017
    “…These findings suggest that mutation-driven perturbations of MAPK pathways are linked to the negative regulation of intratumoral immune response in breast cancer. Modulations of MAPK pathways could be experimentally tested to enhance breast cancer immune sensitivity.…”
  10. 10

    The cost-benefit associated with the maturity of the Antimicrobial Stewardship Program versus prematurity in Heart Hospital of Hamad Medical Corporation in Qatar by Dina Abushanab (10696501)

    Published 2023
    “…</p><h3>Results</h3><p dir="ltr">A total of 668 patients were included in the study (255 in P-ASP versus 413 in M-ASP). With M-ASP, cost of hospital tests use ‘decreased’ by QAR 1,149 per 100-patient beds per year, cost of ASP personnel ‘decreased’ by QAR 125 per 100-patient beds with the M-ASP, cost of drug use ‘increased’ by QAR 176,848 per 100-patient beds, cost of resistance and hospitalization ‘increased’ by QAR 216,279 per 100-patient beds per year. …”
  11. 11

    Rhus coriaria L. (Sumac) Demonstrates Oncostatic Activity in the Therapeutic and Preventive Model of Breast Carcinoma by Peter Kubatka (11008854)

    Published 2020
    “…In the mouse model, R. coriaria at a higher dose (1%) significantly decreased tumor volume by 27% when compared to controls. …”
  12. 12

    Exploring the LDHC Interactome as Novel Candidate Therapeutic Targets to Advance Breast Cancer Precision Medicine by Mariam Ahmed Amin Mohamed Elesnawy (21547187)

    Published 2024
    “…</p><p dir="ltr">Finally, silencing of <i>PKM2 </i>and<i> TUBA1B</i> in breast cancer cells increased DNA damage and decreased cancer cell survival, validating their role in genomic integrity and mimicking our previous observations following silencing of LDHC. …”
  13. 13

    Meta-Heuristic Algorithm-Tuned Neural Network for Breast Cancer Diagnosis Using Ultrasound Images by Ahila A (18394806)

    Published 2022
    “…<div><p>Breast cancer is the most menacing cancer among all types of cancer in women around the globe. …”
  14. 14

    The investigation of treatment design parameters on carbon integration networks by Sabla Y. Alnouri (6331652)

    Published 2023
    “…As a result, this paper focuses on reassessing the performance of carbon integration networks using a more rigorous cost model for the treatment design stage. The effect of utilizing different treatment operating conditions on the overall cost of the treatment stage of CO<sub>2 </sub>(before allocation) is first captured using a detailed cost model. …”
  15. 15

    CD146, a novel target of CD44-signaling, suppresses breast tumor cell invasion by Allal Ouhtit (14153256)

    Published 2017
    “…While the exact function of CD146 in breast cancer (BC) is not completely understood, substantial evidence from our work and others support the hypothesis that CD146 is a suppressor of breast tumor progression. …”
  16. 16

    Genetic Variation in CCL5 Signaling Genes and Triple Negative Breast Cancer: Susceptibility and Prognosis Implications by Jingxuan Shan (4711089)

    Published 2019
    “…In the TCGA TNBC/Basal-like cohort the <b><i>MAP3K21</i></b><b> </b><b>rs1294255-G</b> allele was associated with a decreased OVS. High expression of <i>CCL5</i> in breast tumors was significantly associated with an increased OVS in all BC patients, but particularly in TNBC/Basal-like patients. …”
  17. 17

    Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trial by Mohammed Fasihul Alam (6832217)

    Published 2023
    “…<h3>Background</h3><p dir="ltr">There is limited evidence in the literature on the long-term effectiveness and cost-effectiveness of treatments for Acute Severe Ulcerative Colitis (ASUC). …”
  18. 18

    Comprehensive Transcriptome and Pathway Analyses Revealed Central Role for Fascin in Promoting Triple-Negative Breast Cancer Progression by Rayanah Barnawi (8737584)

    Published 2021
    “…<p dir="ltr">Recent years have witnessed major progress in development of novel therapeutic agents such as chemotherapy, targeted therapy and immune checkpoint inhibitors for breast cancer. However, cancer-related death remains high especially in triple-negative breast cancer (TNBC) due limited therapeutic options. …”
  19. 19

    PD-L1 Expression in Human Breast Cancer Stem Cells Is Epigenetically Regulated through Posttranslational Histone Modifications by Pramod Darvin (153341)

    Published 2019
    “…In this study, we analyzed CpG methylation of PD-L1 promoter in MCF-7 and BT-549 breast cancer cells and tumorspheres derived from them. …”
  20. 20

    An efficient claim management assurance system using EPC contract based on improved monarch butterfly optimization models by K. Mukilan (22224793)

    Published 2024
    “…Conventional construction models typically optimize only a single objective, such as time, cost, or delay, which may not effectively enhance overall performance. …”